Lead Borate Nanoparticles for Selective p53 Mutant Cancer Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatment methods, particularly chemotherapy, often result in significant side effects due to the non-selective killing of both cancerous and healthy cells, highlighting the need for more targeted and effective therapies.

Innovation Solution

The development of nano-sized lead borate compounds synthesized using the buffered-precipitation method, which are selectively toxic to p53 mutant breast cancer cells, allowing for targeted cancer treatment while minimizing harm to healthy cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional chemotherapy is used to treat cancer, then cancer cells are killed, but healthy cells are also damaged causing significant side effects

Engineering Contradiction:

Improvecancer treatment effectivenessVSAvoidside effects on healthy cells

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by functionalizing nanoparticles with specific ligands that bind to receptors overexpressed on cancer cells. This creates a localized effect where the toxic payload is delivered specifically to cancer cells through receptor-mediated endocytosis, while healthy cells without these receptors remain unaffected. The surface functionalization with targeting moieties ensures selective accumulation at the tumor site.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses nanoparticles as intermediary carriers to deliver cytotoxic agents to cancer cells. These nanoparticle mediators protect the therapeutic payload during circulation, enable controlled release at the target site, and provide a platform for combining multiple therapeutic agents. The nanoparticle acts as an intelligent intermediary that responds to the tumor microenvironment for selective drug release.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of manufacture

If non-selective chemotherapy agents are used, then treatment is simple and cost-effective, but selectivity between cancer and healthy cells is poor

Engineering Contradiction:

Improvetreatment simplicityVSAvoidcellular target selectivity

Core Design Contradiction:

Ease of manufactureVSManufacturing precision

Solution Approach 1:

The patent segments the therapeutic system into distinct functional modules: the nanoparticle core for payload delivery, surface ligands for target recognition, and responsive release mechanisms. This segmentation allows independent optimization of each component - the core for stability and loading capacity, the surface for selectivity, and the release mechanism for controlled activation - while maintaining overall system simplicity.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent employs composite nanoparticle materials combining inorganic cores (for stability and imaging capabilities) with organic surface coatings (for biocompatibility and targeting). This composite structure integrates multiple functions within a single therapeutic agent, achieving both manufacturing efficiency and high cellular selectivity through the synergistic properties of different materials.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The nano-sized lead borate compounds demonstrate a selective toxic effect on p53 mutant breast cancer cells, potentially enhancing cancer treatment outcomes while reducing the adverse effects typically associated with conventional chemotherapy.

Implementation Method 1

nano-sized lead borate compounds synthesized using the buffered-precipitation method, which are selectively toxic to p53 mutant breast cancer cells

Methodology Applied

Scientific EffectSelective toxicity:

Implementation Method 2

nano-sized lead borate compounds synthesized using the buffered-precipitation method

Methodology Applied

Scientific EffectPrecipitation: Precipitation

Data Source

PatentUS12329777B2Use of mutant P53 gene targeted lead borate nanoparticles in cancer treatment and production method of these nanoparticles

Publication Date: 2025.06.17 YEDITEPE UNIVERSITESI

AI summary

Use of nano-sized lead borate compounds for treatment purposes due to their selective anticancer activity on p53 mutant breast cancer cell line, T47D is disclosed. The method of synthesizing nano-sized lead borates of the present invention comprises the steps of preparing a borate buffer solution by sodium hydroxide and boric acid, dissolving lead nitrate (and preferably PEG) in distilled water by stirring, mixing the borate buffer solution with the lead nitrate (and preferably PEG) solution, washing the resulting solution with distilled water and drying to remove the impurities.